CA2860008C - Tetraaza-cyclopenta[a]indenyl and their use as positive allosteric modulators - Google Patents

Tetraaza-cyclopenta[a]indenyl and their use as positive allosteric modulators Download PDF

Info

Publication number
CA2860008C
CA2860008C CA2860008A CA2860008A CA2860008C CA 2860008 C CA2860008 C CA 2860008C CA 2860008 A CA2860008 A CA 2860008A CA 2860008 A CA2860008 A CA 2860008A CA 2860008 C CA2860008 C CA 2860008C
Authority
CA
Canada
Prior art keywords
mmol
title compound
tetraaza
hplc
uplc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2860008A
Other languages
English (en)
French (fr)
Other versions
CA2860008A1 (en
Inventor
Dominique Swinnen
Cyril Montagne
Vincent Pomel
Anna Quattropani
Jerome Molette
Patrick Gerber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP11195214.9A external-priority patent/EP2607364A1/en
Priority claimed from EP12171415.8A external-priority patent/EP2674434A1/en
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of CA2860008A1 publication Critical patent/CA2860008A1/en
Application granted granted Critical
Publication of CA2860008C publication Critical patent/CA2860008C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA2860008A 2011-12-22 2012-11-30 Tetraaza-cyclopenta[a]indenyl and their use as positive allosteric modulators Active CA2860008C (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201161578931P 2011-12-22 2011-12-22
EP11195214.9 2011-12-22
EP11195214.9A EP2607364A1 (en) 2011-12-22 2011-12-22 Tetraaza-cyclopenta[a]indenyl and their use as positive allosteric modulators
US61/578,931 2011-12-22
US201261657978P 2012-06-11 2012-06-11
EP12171415.8A EP2674434A1 (en) 2012-06-11 2012-06-11 Tetraaza-cyclopenta[a]indenyl and their use as positive allosteric modulators
US61/657,978 2012-06-11
EP12171415.8 2012-06-11
PCT/EP2012/004968 WO2013091773A1 (en) 2011-12-22 2012-11-30 Tetraaza-cyclopenta[a]indenyl and their use as positive allosteric modulators

Publications (2)

Publication Number Publication Date
CA2860008A1 CA2860008A1 (en) 2013-06-27
CA2860008C true CA2860008C (en) 2020-11-10

Family

ID=48667735

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2860008A Active CA2860008C (en) 2011-12-22 2012-11-30 Tetraaza-cyclopenta[a]indenyl and their use as positive allosteric modulators

Country Status (8)

Country Link
US (1) US9403835B2 (enExample)
EP (1) EP2794608B1 (enExample)
JP (1) JP6112316B2 (enExample)
CN (1) CN104039789B (enExample)
AU (1) AU2012357169B2 (enExample)
CA (1) CA2860008C (enExample)
ES (1) ES2606839T3 (enExample)
WO (1) WO2013091773A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2813505A1 (en) * 2013-06-14 2014-12-17 Asceneuron SA Tetraaza-cyclopenta[a]indenyl derivatives
GB201317363D0 (en) 2013-10-01 2013-11-13 Eisai Ltd Novel compounds
US9844549B2 (en) 2014-08-26 2017-12-19 Astellas Pharma Inc. 2-aminothiazole derivative or salt thereof
UA123262C2 (uk) * 2015-02-11 2021-03-10 Суновіон Фармасьютикалз Інк. ЗШИТІ ДИГІДРО-4H-ПІРАЗОЛО[5,1-c][1,4]ОКСАЗИНІЛОВІ СПОЛУКИ І АНАЛОГИ ДЛЯ ЛІКУВАННЯ ЗАХВОРЮВАНЬ ЦНС
WO2017038650A1 (ja) * 2015-08-28 2017-03-09 積水メディカル株式会社 ベンジル化合物
EA201990399A1 (ru) 2016-07-29 2019-07-31 Суновион Фармасьютикалз, Инк. Соединения, композиции и их применение
CN111183138A (zh) 2017-08-02 2020-05-19 赛诺维信制药公司 异色满化合物以及用途
BR112020012197A2 (pt) 2017-12-21 2020-11-24 Ribon Therapeutics Inc. quinazolinonas como inibidores de parp14

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2441926A1 (en) * 2001-03-27 2002-10-03 Neurogen Corporation (oxo-pyrazolo[1,5a]pyrimidin-2-yl)alkyl-carboxamides
MX2007006896A (es) * 2004-12-15 2007-06-26 Hoffmann La Roche Fenil-metanonas bi- y triciclicas sustituidas como inhibidores del transportador 1 de glicina (glyt-1) para el tratamiento de la enfermedad de alzheimer.
JP5232160B2 (ja) * 2006-11-14 2013-07-10 メルク・シャープ・アンド・ドーム・コーポレーション 糖尿病の治療又は予防のためのジペプチジルペプチダーゼｉｖインヒビターとしての三環式芳香族複素環化合物
WO2011137049A1 (en) * 2010-04-30 2011-11-03 Merck Sharp & Dohme Corp. Heterocyclic quinolizine derived m1 receptor positive allosteric modulators
EP2813505A1 (en) * 2013-06-14 2014-12-17 Asceneuron SA Tetraaza-cyclopenta[a]indenyl derivatives

Also Published As

Publication number Publication date
ES2606839T3 (es) 2017-03-28
JP6112316B2 (ja) 2017-04-12
US9403835B2 (en) 2016-08-02
CN104039789A (zh) 2014-09-10
EP2794608B1 (en) 2016-09-14
US20150018343A1 (en) 2015-01-15
AU2012357169A1 (en) 2014-08-07
JP2015502371A (ja) 2015-01-22
AU2012357169B2 (en) 2017-03-30
CN104039789B (zh) 2016-09-07
WO2013091773A1 (en) 2013-06-27
EP2794608A1 (en) 2014-10-29
CA2860008A1 (en) 2013-06-27

Similar Documents

Publication Publication Date Title
CA2860008C (en) Tetraaza-cyclopenta[a]indenyl and their use as positive allosteric modulators
CA3163218A1 (en) Oxygen-containing heterocyclic compound, preparation method therefor and use thereof
CA3110474C (en) Highly active sting protein agonist compound
JP7682920B2 (ja) Ｉｌ－１７モジュレータとしてのジフルオロシクロヘキシル誘導体
AU2019228568B2 (en) Piperidinyl-3-(aryloxy)propanamides and propanoates
CA2825204A1 (en) Pyrrolopyrazine-spirocyclic piperidine amides as modulators of ion channels
CA2890356A1 (en) Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use
CA3066909A1 (en) Substituted bridged diazepane derivatives and use thereof as task-1 and task-3 inhibitors
CA3156982A1 (en) Arylmethylene heterocyclic compounds as kv1.3 potassium shaker channel blockers
JP2022530474A (ja) 複素環含有化合物、その使用及びそれを含む組成物
JP7749015B2 (ja) 喘息の治療のためのｉｒａｋ４阻害剤としてのｎ－（イミダゾ［１，２－ｂ］ピリダジン－３－イル）－１－シクロヘキシル－２ｈ－インダゾール－５－カルボキサミド及びｎ－（ピラゾロ［１，５－ａ］ピリミジン－３－イル）－１－シクロヘキシル－２ｈ－インダゾール－５－カルボキサミド誘導体
AU2025201400A1 (en) Glycyrrhetinic acid derivatives for treating hyperkalemia
AU2023247317A1 (en) N-(pyrrolidin-3-yl or piperidin-4-yl)acetamide derivatives
CA3034796A1 (en) S1p1 agonist and application thereof
AU2020413555A1 (en) PD-L1 antagonist compound
EP3008068B1 (en) Tetraaza-cyclopenta[a]indenyl derivatives
EP2607364A1 (en) Tetraaza-cyclopenta[a]indenyl and their use as positive allosteric modulators
EP2674434A1 (en) Tetraaza-cyclopenta[a]indenyl and their use as positive allosteric modulators
CN120752233A (zh) 取代的三环衍生物及其药物组合物和用途
JP2022519714A (ja) 高カリウム血症の治療で使用するためのグリチルレチン酸誘導体
CA2972668A1 (en) Heterocyclylalkyne derivatives and their use as modulators of mglur5 receptors

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20171128